India · Delayed Price · Currency is INR Rubicon Research Company Description
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally.
The company develops products in the areas of analgesics/pain management, cardiovascular system, central nervous system, hypokalemia, skeletal muscle relaxants, nicotine replacement therapy, gastrointestinal, metabolic, and immunosuppressant.
Its primary proprietary technologies for drug delivery comprising RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption, as well as RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies.
The company was incorporated in 1999 and is headquartered in Mumbai, India.
| Country | India |
| Founded | 1999 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 1,290 |
| CEO | Parag Sancheti |
Contact Details
Address: MedOne House Mumbai, Maharashtra 400604 India | |
| Phone | 91 22 6141 4000 |
| Website | rubicon.co.in |
Stock Details
| Ticker Symbol | RUBICON |
| Exchange | National Stock Exchange of India |
| Fiscal Year | April - March |
| Reporting Currency | INR |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Parag Suganchand Sancheti | Chief Executive Officer and Executive Director |
| Pratibha S. Pilgaonkar | Co-Founder, MD and Director |
| Sudhir Dhirendra Pilgaonkar | Co-Founder, Chief Commercial Officer and Senior Vice President |
| Sumant Sudhir Pilgaonkar | Senior Vice President of Operations |
| Surabhi Parag Sancheti | Executive Vice President of Business Development and Project Management |
| Narendra N. Borkar | President and Director of Operations (USA) |
| Louis E. L. Coutinho | Global Quality Head |
| Sarabjit Singh | Executive Vice President of Research and Development |